natgillin/translations-raw huggingface dataset:
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups (0.6% versus 0.5% in the clopidogrel + ASA and the placebo + ASA groups, 
V študiji COMMIT je bil skupni delež večjih necerebralnih krvavitev ali cerebralne krvavitve nizek in podoben v obeh skupinah (0,6 % v skupini s klopidogrelom in ASA ter 0,5 % v skupini s placebom in
Other side effects reported with Clopidogrel BMS are: Common side effects (affects 1 to 10 patients in 100): Diarrhoea, abdominal pain, indigestion or 
Drugi neželeni učinki, o katerih so poročali s klopidogrelom so: Pogosti neželeni učinki (pojavijo se pri 1 do 10 od 100 bolnikov): Driska, bolečina v trebuhu, slaba
Then, the usual dose is one 75-mg tablet of Clopidogrel BMS per day to be taken orally with or without food, and at the same time each day. 
Nato je običajni odmerek ena 75-mg tableta zdravila Clopidogrel BMS na dan, ki jo lahko vzamete s hrano ali brez nje; odmerek morate jemati vsak dan ob istem času.
Clopidogrel BMS 300-mg film-coated tablets are oblong, pink, engraved on one side with the number ‘300' and on the other side with the number ‘1332'. 
Clopidogrel BMS 300 mg filmsko obložene tablete so podolgovate, rožnate, z vtisnjeno številko “300” na eni strani in številko “1332” na drugi strani.
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second coprimary endpoint (CV death, MI, stroke or refractory ischaemia). 
Zlasti post hoc analiza podatkov 2172 bolnikov (17 % celotne populacije CURE), ki so jim namestili žilno opornico (Stent-CURE), je ob klopidogrelu v primerjavi s placebom pokazala značilno, 26,2 % zmanjšanje RT za sestavljen primarni opazovani dogodek (srčnožilna smrt, miokardni infarkt, možganska kap) in tudi značilno, 23,9 % zmanjšanje RT za drug sestavljen primarni opazovani dogodek (srčno-žilna smrt, miokardni infarkt, možganska kap ali neodzivna ishemija).
You should specifically tell your doctor if you take a non-steroidal anti-inflammatory drug, usually used to treat painful and/or inflammatory conditions of muscle or joints, or if you take heparin or any other medicine used to reduce blood clotting, or if you take a proton pump inhibitor (e.g, omeprazole) 
Še posebej pomembno je, da obvestite svojega zdravnika, če jemljete nesteroidna protivnetna zdravila, ki se običajno uporabljajo za lajšanje bolečine in/ali vnetja mišic ali sklepov, ali če jemljete heparin ali katerokoli drugo zdravilo, ki se uporablja za zmanjševanje strjevanja krvi, ali če jemljete kakšen zaviralec protonske črpalke (npr. omeprazol) zaradi težav z želodcem.
Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the co-administration of phenobarbital, cimetidine or oestrogen. 
Poleg tega na farmakodinamično aktivnost klopidogrela ni pomembno vplivala sočasna uporaba fenobarbitala, cimetidina ali estrogena.
If Clopidogrel BMS is supplied in PVC/PVDC/aluminium blisters, store below 30°C. 
Zdravilo Clopidogrel BMS, ki je na voljo v PVC/PVDC/alu pretisnih omotih, shranjujte pri temperaturi do 30°C.
- signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Take special care with Clopidogrel BMS'). 
To so lahko znaki redkega zmanjšanja števila določenih krvnih celic, - znaki jetrnih težav, kot je porumenelost kože in/ali oči (zlatenica), ki so lahko, ali pa ne, povezani s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike, in/ali zmedenostjo (glejte poglavje 2 »Bodite posebno pozorni pri jemanju zdravila Clopidogrel BMS«).
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER/Boxes of 30, 50x1, 90 or 100 tablets 
PRETISNI OMOT / Škatle po 30, 50x1, 90 ali 100 tablet
EXPIRY DATE EXP {MM/YYYY} 
EXP: {MM/LLLL}
PVC/PVDC/Aluminium blisters or all aluminium blisters in cardboard cartons containing 7, 14, 28, 30, 84, 90 and 100 film-coated tablets. 
PVC/PVDC/aluminijasti pretisni omoti ali pretisni omoti iz aluminija, ki vsebujejo 7,14, 28, 30, 84, 90
Clopidogrel BMS belongs to a group of medicines called antiplatelet medicinal products. 
Clopidogrel BMS spada v skupino zdravil, ki se imenujejo zaviralci agregacije trombocitov.
While taking Clopidogrel BMS, consult your doctor about the breast-feeding of a baby. 
Med jemanjem zdravila Clopidogrel BMS se o dojenju posvetujte z zdravnikom.
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to 18.7 [p=0.258]). 
Pri analizi podskupin glede na vključitveni pogoj (miokardni infarkt, ishemična kap in periferna arterijska bolezen/PAD/) je videti najmočnejšo korist (doseganje statistične značilnosti pri p=0,003) pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi miokardni infarkt) (zmanjšanje RT=23,7 %; IZ: 8,9 do 36,2), in šibkejšo (ni bila pomembno različna od ASA) pri bolnikih s kapjo (zmanjšanje RT=7,3 %; IZ: -5,7 do 18,7 [p=0,258]).
Acute liver failure, hepatitis, abnormal liver function test 
Akutna odpoved jeter, hepatitis, nenormalni testi jetrne funkcije podkožja kožne krvavitve (purpura)
Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions that receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4). 
Zaviralci glikoproteina IIb/IIIa: klopidogrel moramo uporabljati previdno pri bolnikih, ki imajo lahko tveganje za povečano krvavitev zaradi poškodbe, kirurškega posega ali drugih patoloških stanj, ko prejemajo sočasno zaviralce glikoproteina IIb/IIIa (glejte poglavje 4.4).
The other ingredients are mannitol (E421), hydrogenated castor oil, microcrystalline cellulose, macrogol 6000 and low-substituted hydroxypropylcellulose in the tablet core, and lactose (milk sugar), hypromellose (E464), triacetin (E1518), red iron oxide (E172), titanium dioxide (E171), and carnauba 
Pomožne snovi so: manitol (E421), hidrogenirano ricinusovo olje, mikrokristalna celuloza, makrogol 6000 in delno substituirana hidroksipropilceluloza v jedru tablete in laktoza (mlečni sladkor), hipromeloza (E464), triacetin (E1518), rdeč železov oksid (E172), titanov dioksid (E171) in
The other ingredients are mannitol (E421), hydrogenated castor oil, microcrystalline cellulose, macrogol 6000 and low-substituted hydroxypropylcellulose in the tablet core, and lactose (milk sugar), hypromellose (E464), triacetin (E1518), red iron oxide (E172), titanium dioxide (E171), and carnauba wax in the tablet coating. 
Pomožne snovi so: manitol (E421), hidrogenirano ricinusovo olje, mikrokristalna celuloza, makrogol 6000 in delno substituirana hidroksipropilceluloza v jedru tablete in laktoza (mlečni sladkor), hipromeloza (E464), triacetin (E1518), rdeč železov oksid (E172), titanov dioksid (E171) in karnauba vosek v oblogi tablete.
Clopidogrel BMS is supplied in cardboard cartons containing 4x1, 30x1 and 100x1 tablets in all aluminium perforated unit-dose blisters. 
Zdravilo Clopidogrel BMS je na voljo v škatlah, ki vsebujejo 4x1, 30x1 in 100x1 tableto v perforiranih pretisnih omotih za enkratni odmerek, ki so v celoti iz aluminija.
Although the evidence of CYP2C19 inhibition varies within the class of Proton Pump Inhibitors, clinical studies suggest an interaction between clopidogrel and possibly all members of this class. 
Izsledki o zaviranju CYP2C19 se v skupini zaviralcev protonske črpalke sicer razlikujejo, vendar klinične študije kažejo na medsebojno delovanje med klopidogrelom in morda vsemi pripadniki te skupine.
• If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain; 
BMS; - če imate zdravstveno stanje, ki trenutno povzroča krvavitev, kot je rana na želodcu ali krvavitev v možganih; - če imate hudo jetrno obolenje.
Aluminium perforated unit-dose blisters in cardboard cartons containing 4x1, 30x1 and 100x1 film-coated tablets. 
Aluminijski perforirani pretisni omoti za enkratni odmerek v kartonskih škatlah, ki vsebujejo 4 x 1, 30 x 1 in 100 x 1 filmsko obloženo tableto.
- You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral 
Clopidogrel BMS vam je predpisan za pomoč pri preprečevanju nastajanja krvnih strdkov in za zmanjšanje tveganja teh hudih dogodkov, ker: - imate stanje otrdelih arterij (znano tudi kot ateroskleroza), in - ste predhodno doživeli srčni napad, kap ali imeli stanje, ki je znano kot periferna arterijska
Clopidogrel BMS also contains hydrogenated castor oil which may cause stomach upset or diarrhoea. 
Zdravilo Clopidogrel BMS vsebuje tudi hidrogenirano ricinusovo olje, ki lahko povzroči želodčne
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p = 0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event. 
Pri analizi vključenih bolnikov (“intention to treat analysis”) so v skupini, ki je prejemala klopidogrel, opazili 939 dogodkov in v skupini, ki je prejemala ASA, 1.020 dogodkov (zmanjšanje relativnega tveganja (RT) 8,7 %, [95 % IZ: 0,2 do 16,4]; p=0,045), kar ustreza preprečevanju pojava novega ishemičnega dogodka na vsakih 1.000 bolnikov, zdravljenih 2 leti, dodatnim 10 [IZ: 0 do 20] bolnikom.
EU/1/08/464/015 - Cartons of 4x1 film-coated tablets in all aluminium perforated unit-dose blisters EU/1/08/464/016 - Cartons of 30x1 film-coated tablets in all aluminium perforated unit-dose blisters EU/1/08/464/017 - Cartons of 100x1 film-coated tablets in all aluminium perforated unit-dose blisters 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/08/464/015 4x1 filmsko obloženih tablet EU/1/08/464/016 30x1 filmsko obloženih tablet EU/1/08/464/017 100x1 filmsko obloženih tablet
What Clopidogrel BMS looks like and contents of the pack 
Izgled zdravila Clopidogrel BMS in vsebina pakiranja
SPECIAL STORAGE CONDITIONS Store below 30°C (for PVC/PVDC/aluminium blisters) Or No special storage conditions (for all aluminium blisters) 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte pri temperaturi do 30°C (za PVC/PVDC/alu pretisne omote).
If Clopidogrel BMS is supplied in all aluminium blisters, it does not require any special storage conditions. 
Za shranjevanje zdravila Clopidogrel BMS, ki je na voljo v aluminijastih pretisnih omotih, niso potrebna posebna navodila.
• Patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). 
akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca), vključno z bolniki, katerim je bil vstavljen stent po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA - acetylsalicylic acid).
Intermediate metabolism: CYP2C19*1/*2 or *1/*3 
Srednja presnova: CYP2C19*1/*2 ali *1/*3
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically 
Vendar pa so bolniki, ki so bili vključeni v klinično preskušanje klopidogrela, prejemali sočasno različna zdravila, vključno z diuretiki, zaviralci adrenergičnih receptorjev beta, zaviralci angiotenzinske konvertaze (ACEI), kalcijevimi antagonisti, učinkovinami za zniževanje holesterola, koronarnimi vazodilatatorji, antidiabetiki (vključno z insulinom), antiepileptičnimi učinkovinami in antagonisti glikoproteina IIb/IIIa, brez dokazov o klinično
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme), angioedema, rash erythematous, urticaria, eczema, lichen planus Musculo-skeletal bleeding (haemarthrosis), arthritis, arthralgia, myalgia 
Bulozen dermatitis (toksična epidermalna nekroliza, StevensJohnsonov sindrom, multiformni eritem), angioedem, eritematozen izpuščaj, urtikarija, ekcem, lihen planus
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebotreated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group. 
Število bolnikov s primarnim opazovanim dogodkom (srčno-žilna smrt, MI, kap ali neodzivna ishemijo) je bilo 1.035 (16,5 %) v skupini zdravljeni s klopidogrelom in 1.187 (18,8 %) v skupini s placebom, to je 14 % zmanjšanje relativnega tveganja (95 % IZ od 6 % -21 %, p=0,0005) za skupino, zdravljeno s klopidogrelom.
Bruising 
Vrtoglavica
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day. 
Po večkratnih odmerkih 75 mg klopidogrela na dan, je bila pri osebah s hudo ledvično boleznijo (očistek kreatinina 5 do 15 ml/min)inhibicija z ADP sprožene agregacije trombocitov manjša (25 %) od tiste, opažene pri zdravih osebah.
• if you have had a clot in an artery of your brain (ischaemic stroke) which occurred within the 
• če ste imeli strdek v možganski arteriji (ishemična kap), ki se je pojavil v zadnjih sedmih dneh
For the maintenance dose, clopidogrel should be given as a single daily dose of 75 mg with or without food. 
Za vzdrževalno zdravljenje je treba klopidogrel uporabljati v enkratnem odmerku 75 mg na dan, s hrano ali brez nje.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36 % odds reduction in favor of clopidogrel (95% CI: 24, 47%; p < 0.001), mainly related to a reduction in occluded infarct-related arteries. 
Primarni opazovani dogodek je bil opažen pri 15,0 % bolnikov v skupini s klopidogrelom in 21¸7 % bolnikov v skupini s placebom, kar predstavlja absolutno zmanjšanje za 6,7 % in 36 % zmanjšanje verjetnosti v prid klopidogrela (95 % IZ od 24 % do 47 %; p < 0,001) v glavnem zaradi zmanjšanja zaradi infarkta zamašenih arterij.
− Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily). 
- Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca): zdravljenje moramo začeti z enkratnim udarnim odmerkom 300 mg klopidogrela in nadaljevati s 75 mg enkrat na dan (s 75 mg do 325 mg acetilsalicilne kisline (ASA) dnevno).
In PVC/PVDC/aluminium blisters, store below 30°C. 
V PVC/PVDC/alu pretisnih omotih shranjujte pri temperaturi do 30°C.
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors. 
Kot pri drugih antitrombotikih, moramo klopidogrel uporabljati previdno pri bolnikih s tveganjem za povečano krvavitev zaradi poškodbe, kirurškega posega ali drugih patoloških stanj in pri bolnikih, ki so na zdravljenju z ASA, heparinom, zaviralci glikoproteina IIb/IIIa ali nesteroidnimi protivnetnimi zdravili (NSAIDs) vključno z zaviralci COX-2.
Pink, oblong, engraved with «300» on one side and «1332» on the other side. 
Rožnate, podolgovate filmsko obložene tablete z vtisnjeno številko "300" na eni strani in "1332" na
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors, or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors. 
Kot pri drugih antitrombotikih, moramo klopidogrel uporabljati previdno pri bolnikih s tveganjem za povečano krvavitev zaradi poškodbe, kirurškega posega ali drugih patoloških stanj in pri bolnikih, ki so na zdravljenju z ASA, heparinom, zaviralci glikoproteina IIb/IIIa ali nesteroidnimi protivnetnimi zdravili (NSAIDs), vključno z zaviralci COX-2.
Important information about some of the ingredients of Clopidogrel BMS: 
Pomembne informacije o nekaterih sestavinah zdravila Clopidogrel BMS Zdravilo Clopidogrel BMS vsebuje laktozo .
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER / Box of 4x1, 30x1 or 100x1 tablets 
PRETISNI OMOT /Škatle po 4x1, 30x1 ali 100x1 tablet
HOW TO STORE CLOPIDOGREL BMS 
SHRANJEVANJE ZDRAVILA CLOPIDOGREL BMS
Clopidogrel BMS 75 mg 
PODATKI V BRAILLOVI PISAVI Clopidogrel BMS 75 mg
Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP. 
Zavrta je tudi agregacija trombocitov, ki jo izzovejo drugi agonisti kot ADP, ker pride do blokade ojačenja trombocitne
Skin and subcutaneous tissue disorders 
Bolezni mišičnoskeletnega sistema in vezivnega tkiva
- ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300-mg loading dose in combination with ASA and with or without thrombolytics. 
- Akutni miokardni infarkt z elevacijo ST spojnice: klopidogrel je potrebno dajati v enkratnem dnevnem odmerku 75 mg, zdravljenje pa je potrebno začeti s 300 mg udarnim odmerkom v kombinaciji z ASA ter z/brez uporabe trombolitikov.
In CLARITY, there was an overall increase in bleeding in the clopidogrel + ASA group (17.4%) vs. the placebo + ASA group (12.9%).The incidence of major bleeding was similar between groups (1.3% versus 1.1% for the clopidogrel + ASA and the placebo + ASA groups, respectively). 
V študiji CLARITY je v skupini s klopidogrelom in ASA prišlo do splošnega povečanja krvavitev (17,4 %) v primerjavi s skupino s placebom in ASA (12,9 %).
This medicinal product does not require any special storage conditions. 
6.4 Posebna navodila za shranjevanje Za shranjevanje zdravila niso potrebna posebna navodila.
- Clopidogrel BMS 300 mg film-coated tablets 
− Clopidogrel BMS 300 mg filmsko obložene tablete
− ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300-mg loading dose in combination with ASA and with or without thrombolytics. 
Akutni miokardni infarkt z elevacijo ST spojnice: klopidogrel je potrebno dajati v enkratnem dnevnem odmerku 75 mg, zdravljenje pa je potrebno začeti s 300 mg udarnim odmerkom v kombinaciji z ASA ter z/brez uporabe trombolitikov.
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 2 ‘Take special care with 
Če pa vas glede krvavitve skrbi, se nemudoma posvetujte z zdravnikom (glejte poglavje 4 »MOŽNI NEŽELENI
Each tablet contains 300 mg of clopidogrel (as hydrogen sulphate). 
Vsaka tableta vsebuje 300 mg klopidogrela v obliki klopidogrelijevega hidrogensulfata.
- Clopidogrel BMS 75 mg film-coated tablets 
- Clopidogrel BMS 75 mg filmsko obložene tablete
Clopidogrel BMS 75 mg film-coated tablets clopidogrel 
Clopidogrel BMS 75 mg filmsko obložene tablete klopidogrel
NAME OF THE MEDICINAL PRODUCT Clopidogrel BMS 300 mg film-coated tablets 
IME ZDRAVILA Clopidogrel BMS 300 mg filmsko obložene tablete
EU/1/08/464/017 100x1 film-coated tablets 
EU/1/08/464/017 - Škatle s 100 x 1 filmsko obloženih tablet v perforiranih pretisnih omotih za enkratni odmerek, ki so v celoti iz aluminija.
NAME OF THE MEDICINAL PRODUCT Clopidogrel BMS 75 mg film-coated tablets 
IME ZDRAVILA Clopidogrel BMS 75 mg filmsko obložene tablete
While you are taking Clopidogrel BMS: 
Če ste prenehali jemati zdravilo Clopidogrel BMS:
Clopidogrel BMS 300-mg film-coated tablets clopidogrel 
Clopidogrel BMS 300 mg filmsko obložene tablete klopidogrel
Pharmacotherapeutic group: platelet aggregation inhibitors excl. heparin, ATC Code: B01AC-04. 
Farmakoterapevtska skupina: Zaviralci agregacije trombocitov brez heparina,
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate). 
Ena filmsko obložena tableta vsebuje 75 mg klopidogrela v obliki klopidogrelijevega hidrogensulfata.
Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of drugs that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel and a reduction in clinical efficacy. 
Zato je mogoče pričakovati, da uporaba zdravil, ki zavrejo delovanje tega encima, zmanjša koncentracijo aktivnega presnovka klopidogrela in tako zmanjša njegovo klinično učinkovitost.
Each tablet contains 75 mg of clopidogrel (as hydrogen sulphate). 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena tableta vsebuje 75 mg klopidogrela (v obliki klopidogrelijevega hidrogensulfata).
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 300 mg of clopidogrel (as hydrogen sulphate). 
Ena filmsko obložena tableta vsebuje 300 mg klopidogrela v obliki klopidogrelijevega hidrogensulfata.
Pink, round, biconvex, engraved with «75» on one side and «1171» on the other side. 
Rožnate, okrogle, bikonveksne filmsko obložene tablete, z vtisnjeno številko "75" na eni strani in
In all aluminium blisters, this medicinal product does not require any special storage conditions. 
Za shranjevanje zdravila v aluminijastih pretisnih omotih niso potrebna posebna navodila.
Always take Clopidogrel BMS exactly as your doctor has told you. 
Pri jemanju zdravila Clopidogrel BMS natančno upoštevajte zdravnikova navodila.
Vertigo 
Hematurija
EFFECTIVE USE OF THE MEDICINAL PRODUCT 
GYÓGYSZERKERESKEDELMI KFT
New cardiovascular events 
Psihiatrične motnje
Mixtard will start to lower your blood sugar about 30 minutes after you inject it, and the effect will last for approximately 24 hours. 
Zdravilo Mixtard začne sladkor v krvi zniževati približno 30 minut po uporabi, njegov učinek pa traja približno 24 ur.
• Drink alcohol, see Mixtard with alcohol in section 2. 
• če pijete alkohol, glejte podpoglavje Zdravilo Mixtard skupaj z alkoholom v poglavju 2.
Mixtard dosing is individual and determined in accordance with the needs of the patient. 
Odmerjanje zdravila Mixtard je individualno in odvisno od potreb posameznega bolnika.
This should be kept in mind if treatment with the combination of pioglitazone and Mixtard is considered. 
To je treba upoštevati pri načrtovanju zdravljenja s kombinacijo pioglitazona in zdravila Mixtard.
Mixtard can be used during pregnancy. 
Zdravilo Mixtard se lahko uporablja med nosečnostjo.
After stabilisation of the patient's blood glucose, adjustment of the dose should be considered (see sections 4.8 and 4.9). 
Po ureditvi bolnikove glukoze v krvi je treba razmisliti o prilagoditvi odmerka (glejte poglavji 4.8 in